Compare EM & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EM | ACRS |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 296.7M | 311.0M |
| IPO Year | 2021 | 2015 |
| Metric | EM | ACRS |
|---|---|---|
| Price | $1.20 | $4.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $1.25 | ★ $10.20 |
| AVG Volume (30 Days) | 130.8K | ★ 1.3M |
| Earning Date | 06-02-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,683,000.00 |
| Revenue This Year | $3.30 | N/A |
| Revenue Next Year | $5.26 | $4.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.01 | $1.22 |
| 52 Week High | $1.46 | $4.94 |
| Indicator | EM | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 66.07 | 69.13 |
| Support Level | $1.16 | $2.67 |
| Resistance Level | $1.42 | N/A |
| Average True Range (ATR) | 0.02 | 0.27 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 73.68 | 84.13 |
Smart Share Global Ltd is a consumer tech company providing mobile device charging services through an extensive online and offline network in China. It provides service through power banks, placed in POIs operated by location partners, such as entertainment venues, restaurants, shopping centers, hotels, transportation hubs, and public spaces. Geographically, the company generates revenue from the PRC. The company has two segments, the mobile device charging segment and the PV business segment. The company generates the majority of its revenue from the mobile device charging segment.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.